ArticleBMC cancer2016
Chemotherapy for intracranial ependymoma in adults.
Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- A brief history of ependymoma.Neuro-oncology · 2026Review
- Clinical Features and Prognostic Indicators for Brainstem Ependymomas : A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.Journal of Korean Neurosurgical Society · 2026Article
- Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review.Frontiers in oncology · 2026Article
- Pharmacological Phase I Clinical Trials in Pediatric Brain Tumors (1990-2024): A Historical Perspective.Oncology research · 2025Review
- Pediatric-Like Brain Tumors in Adults.Advances and technical standards in neurosurgery · 2024Review
- Prognostic factors of pediatric ependymomas at a National Cancer Reference Center in Peru.Frontiers in oncology · 2023Article
- Survival After Resection of Newly-Diagnosed Intracranial Grade II Ependymomas: An Initial Multicenter Analysis and the Logistics of Intraoperative Magnetic Resonance Imaging.World neurosurgery · 2022Article
- Ependymoma: Evaluation and Management Updates.Current oncology reports · 2022Review
- Review
- An Overview of Intracranial Ependymomas in Adults.Cancers · 2021Review
- A Rare Case of Metastatic Primary Peritoneal Ependymoma: A Case Report and Literature Review.Case reports in oncological medicine · 2020Article
- Personalizing age-specific survival prediction and risk stratification in intracranial grade II/III ependymoma.Cancer medicine · 2020Article
- Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Review
- Evidence-Based Practice: Temozolomide Beyond Glioblastoma.Current oncology reports · 2019Review
- EANO guidelines for the diagnosis and treatment of ependymal tumors.Neuro-oncology · 2018Review
- Article
- Simultaneous cerebrospinal fluid and hematologic metastases in a high-grade ependymoma.Surgical neurology international · 2018Article
- Recent Advances in the Classification and Treatment of Ependymomas.Current treatment options in oncology · 2017Review
- Multiple intradural-extramedullary spinal ependymomas including tumors with different histological features.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2017Article
- The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.Acta neuropathologica · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpendymal tumors in adults are rare, accounting for less than 4% of primary tumors of the central nervous system in this age group. The low prevalence of intracranial ependymoma in adults limits the ability to perform clinical trials. Therefore, treatment decisions are based on small, mostly retrospective studies and the role of chemotherapy has remained unclear.
methodsWe performed a retrospective study on 17 adult patients diagnosed with intracranial World Health Organisation grade II or III ependymoma, who were treated with chemotherapy at any time during the disease course. Benefit from chemotherapy was estimated by applying Macdonald criteria. Progression-free (PFS) and overall survival (OS) were calculated from start of chemotherapy, using the Kaplan-Meier method.
resultsEleven patients had supratentorial and 6 infratentorial tumors. Ten patients were treated with temozolomide (TMZ), 3 with procarbazine/lomustine/vincristine (PCV), 3 with platinum-based chemotherapy and 1 patient received epirubicin/ifosfamide. Response rates were as follows: TMZ 8/10 stable disease; PCV 3/3 stable disease; platinum-based chemotherapy 1/3 partial response; epirubicin/ifosfamide 1/1 complete response. PFS rates at 6, 12 and 24 months were 52.9, 35.3 and 23.5%. OS rates at 6, 12 and 24 months were 82.4, 82.4 and 70.1%. There was no indication for a favourable prognostic role of O(6)-methylguanyl-DNA-methyltransferase (MGMT) promoter methylation which was detected in 3/12 investigated tumors.
conclusionsSurvival outcomes in response to chemotherapy in adult intracranial ependymoma patients vary substantially, but individual patients may respond to any kind of chemotherapy. There were too few patients to compare survival data between chemotherapeutic subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.